Nicholas Piramal India Limited's leading medicinal chemist, Dr. Bansi Lal, will be presenting their invention of a novel class of anticancer molecules at the Gordon Research Conferences (Medicinal Chemistry) in New London, New Hampshire, USA.
The Gordon Research Conferences are held annually in the USA with the mission to "provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies."
Dr. Bansi Lal and his team of scientists at NPIL's R&D Centre, the Quest Institute of Life Sciences, invented a novel class of anticancer agents belonging to the chemical grouping called pyrrolidines. Their poster at the conference is titled, " A novel class of anticancer agents: Pyrrolidines with substituted flavones as Cdk4 inhibitors."
One of the molecules invented by Dr. Bansi Lal and his group at QILS (code-named P-276-00) has been selected as the lead candidate in NPIL's oncology programme, and is currently undergoing advanced toxicology testing prior to entering human clinical trials, the company release said.